Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMonash University
About this trial
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests.
Participants will have a single blood test and speech test, and will be followed up at 12-months to complete questionnaires and cognitive scales over the phone. The speech test will also be completed again at 12-months.
Individuals at risk of a Fronto-temporal dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample.
Eligibility criteria
Qualifiers
All patients presenting to Eastern Health services with a cognitive complaint or potential neurodegenerative disorder
Disqualifiers
Prognosis <12 months
No cognitive complaint
Patients not involved within the single healthcare network
Trial design
Treatments tested in this trial
- Venepuncture
Treatment groups
No treatment groups listed
Locations
2Box Hill Hospital3128, Box HillVictoria, Australia
Wantirna Health3152, WantirnaVictoria, Australia
Sponsors and collaborators
Monash University
Lead sponsor
Eastern Health
Collaborator
University of Melbourne
Collaborator
Wake Forest University
Collaborator
Deakin University
Collaborator
The Florey Institute of Neuroscience and Mental Health
Collaborator
Invitae Corporation
Collaborator
Redenlab
Collaborator
Source ClinicalTrials.gov